Vincerx Pharma Inc. (VINC) has shared promising results from its Phase 1 dose-escalation study of VIP943, an innovative antibody-drug conjugate (ADC) designed to treat relapsed/refractory acute myeloid leukemia (AML), higher-risk myelodysplastic syndrome (HR-MDS), and B-cell acute lymphoblastic leukemia (B-ALL). The study has yielded two complete responses so far, highlighting the safety, tolerability, and potential of VIP943, further validating the efficacy of their VersAptx Platform technology. The company anticipates releasing further insights from the ongoing study by the end of the year.
In parallel, Vincerx is evaluating VIP236, a pioneering small molecule drug conjugate (SMDC), in another Phase 1 dose-escalation study focused on patients with advanced solid tumors. The trial indicates that VIP236 maintains a positive safety profile across 29 patients, avoiding the severe side effects typical of camptothecins, such as life-threatening diarrhea, severe stomatitis/mucositis, or interstitial lung disease. These encouraging findings suggest VIP236's potential as a robust combination therapy for advanced cancers.
Given these promising results, Vincerx plans to seek a strategic partner to further the development of VIP236, aiming to optimize its benefits for patients. By transitioning VIP236 into a partnership model, Vincerx looks to streamline its operations and concentrate on advancing its primary ADC, VIP943.
